Sangamo Therapeutics, Inc. (SGMOQ)
0.1423
-0.02
(-11.17%)
USD |
OTCM |
Aug 21, 16:00
Sangamo Therapeutics Enterprise Value : 50.70M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 50.70M |
| August 20, 2026 | 58.11M |
| August 19, 2026 | 58.44M |
| August 18, 2026 | 57.82M |
| August 17, 2026 | 61.47M |
| August 14, 2026 | 64.24M |
| August 13, 2026 | 60.10M |
| August 12, 2026 | 55.34M |
| August 11, 2026 | 51.82M |
| August 10, 2026 | 40.63M |
| August 07, 2026 | 38.14M |
| August 06, 2026 | 37.94M |
| August 05, 2026 | 32.92M |
| August 04, 2026 | 28.66M |
| August 03, 2026 | 27.46M |
| July 31, 2026 | 22.07M |
| July 30, 2026 | 21.22M |
| July 29, 2026 | 20.25M |
| July 28, 2026 | 19.59M |
| July 27, 2026 | 18.47M |
| July 24, 2026 | 18.67M |
| July 23, 2026 | 21.99M |
| July 22, 2026 | 18.67M |
| July 21, 2026 | 19.09M |
| July 20, 2026 | 22.78M |
| Date | Value |
|---|---|
| July 17, 2026 | 18.67M |
| July 16, 2026 | 19.92M |
| July 15, 2026 | 18.67M |
| July 14, 2026 | 23.23M |
| July 13, 2026 | 21.99M |
| July 10, 2026 | 33.17M |
| July 09, 2026 | 26.54M |
| July 08, 2026 | 19.09M |
| July 07, 2026 | 20.06M |
| July 06, 2026 | 19.92M |
| July 02, 2026 | 22.78M |
| July 01, 2026 | 15.36M |
| June 30, 2026 | 14.08M |
| June 29, 2026 | 13.45M |
| June 26, 2026 | 10.39M |
| June 25, 2026 | 7.903M |
| June 24, 2026 | 10.40M |
| June 23, 2026 | 22.40M |
| June 22, 2026 | 63.93M |
| June 18, 2026 | 64.04M |
| June 17, 2026 | 65.69M |
| June 16, 2026 | 62.17M |
| June 15, 2026 | 60.10M |
| June 12, 2026 | 54.30M |
| June 11, 2026 | 51.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sarepta Therapeutics, Inc. | 2.242B |
| Anixa Biosciences, Inc. | 111.10M |
| Vicapsys Life Sciences, Inc. | 47.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.00M |
| Revenue (Quarterly) | 1.442M |
| Total Expenses (Quarterly) | 32.44M |
| EPS Diluted (Quarterly) | -0.0796 |
| Gross Profit Margin (Quarterly) | 39.18% |
| Profit Margin (Quarterly) | -2.15K% |
| Earnings Yield | -269.1% |
| Normalized Earnings Yield | -250.74 |